Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (ticker: BCTG) is a precision oncology biopharmaceutical company that completed a business combination with BCTG Acquisition Corp, a special purpose acquisition company that conducted its IPO in 2020. The company focuses on identifying and developing cancer therapies through a synthetic lethality approach, targeting the biotechnology sector. On September 10, 2021, Tango Therapeutics filed an S-1 registration statement with the SEC, accession number 0001193125-21-269987, in connection with the de-SPAC transaction and registration of shares for the combined company. The merger marked Tango's transition to a publicly traded entity on Nasdaq. For complete filing history, investor data, and deal analytics on BCTG and hundreds of other SPAC transactions, create a free account at SpacDesk.